Photo by atikahakhtar from unsplash
1 Azevedo A, Bettencourt A, Selores M, et al. Biosimilar agents for psoriasis treatment: the perspective of portuguese patients. Acta M ed Port 2018; 31: 496–500. 2 Puig L, L… Click to show full abstract
1 Azevedo A, Bettencourt A, Selores M, et al. Biosimilar agents for psoriasis treatment: the perspective of portuguese patients. Acta M ed Port 2018; 31: 496–500. 2 Puig L, L opez-Ferrer A. Biosimilars for the treatment of psoriasis. Exp Opin Biol Ther 2019; 19: 993–1000. 3 Barker J, Girolomoni G, Egeberg A, et al. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat 2019; 1–7. https://doi.org/10.1080/09546634. 2019.1610553. 4 Reynolds KA, Pithadia DJ, Lee EB, et al. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. Exp Opin Drug Saf 2020; 19: 459–466. 5 Reynolds KA, Pithadia DJ, Lee EB, et al. Safety and effectiveness of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis. Am J Clin Dermatol 2020; 21: 483–491.
Journal Title: International Journal of Dermatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!